Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions, recently announced a major distribution deal with Marketing Media Enterprises, LLC (MME), an Orlando Florida medical products distributor serving the direct-to-consumer and military market. The initial $2M order from MME is the first of what are expected to be recurring orders to supply its merchant customer base, and MME has agreed to prominently feature CellerateRX within its direct-to-consumer sales channels.
CellerateRX’s activated collagen delivers the essential benefits of collagen to a wound immediately, where other forms of native, intact collagen in commercially available products require time for the body to prepare the collagen for use in the wound healing process. In people with compromised health or circulation, the difference in wound healing can be significant.
CellerateRX is FDA cleared for all wound types except for 3rd degree burns and is available in both powder and gel form. In addition to being used in healthcare settings throughout the country, CellerateRX is easily applied by patients by themselves at home. CellerateRX® is safe, non-toxic, and easy to use.
According to Deborah Jenkins Hutchinson, President of Wound Management Technologies: “The need for effective wound care treatment has never been greater, as our population ages and type 2 diabetes affects more and more Americans. In light of these statistics, the company has positioned CellerateRX to be a leading wound care product within many different sales channels.”
Jenkins-Hutchinson will be delivering an investor presentation about the company at AdvaMed 2011: The MedTech Conference on Wednesday, September 28 at 9:10am at the Walter E. Washington Convention Center in Washington, D.C. in room 204a.
AdvaMed 2010 is the premier MedTech conference for business leaders, entrepreneurs, policy-makers, media, financiers, and other industry stakeholders from around the world. Ms. Jenkins-Hutchinson’s presentation will focus on Wound Management Technologies’ 2011 progress and Q3/Q4′s emerging opportunities.
For more information, visit www.AdvaMed2011.com.